Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Peter Tummino"'
Autor:
Lukas Lercher, Nina Simon, Andreas Bergmann, Marcel Tauchert, David Bochmann, Tarig Bashir, Torsten Neuefeind, Daniel Riley, Ben Danna, Paul Krawczuk, Vineet Pande, Aaron Patrick, Ruth Steele, Weixue Wang, Brent Rupnow, Peter Tummino, Sujata Sharma, Michael Finley
Publikováno v:
SLAS Discovery, Vol 27, Iss 5, Pp 306-313 (2022)
The dysregulation of the PRC1/2 complex plays a key role in lineage plasticity in prostate cancer and may be required to maintain neuroendocrine phenotype. [1] CBX2, a key component of the canonical PRC1 complex, is an epigenetic reader, recognizing
Externí odkaz:
https://doaj.org/article/b449f25b6fca45bd9efb5d3d88bd7ec4
Autor:
David Ciccone, Vad Lazari, Ian Linney, Michael Briggs, Samantha Carreiro, Joshua McElwee, Ian Waddell, Chris Hill, Christine Loh, Peter Tummino, Alan Collis, Neelu Kaila
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/11f4cb29b7ee40dfb6994ec7c3098018
Autor:
Fred Csibi-Levin, Silvana Leit, David L. Laughton, Tom Baker, Suzanne L. Jacques, Beth Browning, Angela V. Toms, Samantha Garside, Simon D'Archivio, Katarzyna Kopycka, Xiaohua Zhu, Allan M. Jordan, Stuart Thomson, Christine Loh, Peter Tummino, David N. Ciccone
Publikováno v:
Cancer Research. 82:589-589
Introduction: Casitas B-lineage lymphoma b (Cbl-b), a RING finger E3 ligase and a member of a highly conserved family of Cbl proteins, catalyzes the ubiquitination of substrate proteins to regulate multiple signaling events in a variety of cell types
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53a52ecbb63015d93d013097f6369635
https://doi.org/10.1158/1538-7445.am2022-589
https://doi.org/10.1158/1538-7445.am2022-589
Autor:
Joshua McElwee, Vad Lazari, Peter Tummino, Chris Hill, Ian D. Waddell, Ian Linney, Neelu Kaila, Christine Loh, Alan Collis, David Ciccone, Samantha Carreiro, Michael Briggs
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background HPK1, a member of the MAP4K family of protein serine/threonine kinases, is involved in regulating signal transduction cascades in cells of hematopoietic origin. Recent data from HPK1 knockout animals and kinase-inactive knock-in animals un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::196ad7e99d2841a5f8ab6c243766224d
https://doi.org/10.1136/jitc-2020-sitc2020.0685
https://doi.org/10.1136/jitc-2020-sitc2020.0685
Autor:
Neelu Kaila, Vad Lazari, Michael Briggs, Alan Collis, Ian Linney, Samantha Carreiro, Peter Tummino, Christine Loh, David Ciccone, Joshua J McElwee
Publikováno v:
Cancer Research. 81:1649-1649
Background: HPK1, a member of the MAP4K family of protein serine/threonine kinases, is involved in negatively regulating signal transduction cascades in cells of hematopoietic origin. Recent data generated using potent and highly selective HPK1 inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::202fe891d0b28373e36b8eee6f84bc86
https://doi.org/10.1158/1538-7445.am2021-1649
https://doi.org/10.1158/1538-7445.am2021-1649
Autor:
David Ciccone, C. Loh, Samantha Carreiro, Alan Collis, Vad Lazari, Ian Linney, Peter Tummino, Neelu Kaila, Ian D. Waddell, Chris Hill, Michael Briggs
Publikováno v:
European Journal of Cancer. 138:S20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b4c4cb552e0e20879198ee745df7857
https://doi.org/10.1016/s0959-8049(20)31118-7
https://doi.org/10.1016/s0959-8049(20)31118-7
Autor:
John Montana, Neelu Kaila, Mark Ashwell, Michael Briggs, Jennifer Rocnik, David Ciccone, Vad Lazari, Peter Tummino, Ian Linney, Christine Loh, Alan Collis
Publikováno v:
Cancer Research. 80:942-942
Introduction: HPK1, a member of the MAP4K family of protein serine/threonine kinases, is involved in regulating signal transduction cascades in cells of hematopoietic lineage. Recent data from HPK1 knockout animals and kinase-inactive knock-in animal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37f77f4773fa92e64cb4670df9e70049
https://doi.org/10.1158/1538-7445.am2020-942
https://doi.org/10.1158/1538-7445.am2020-942
Autor:
Aristeidis Chaidos, Valentina Caputo, Ilaria Marigo, Binbin Liu, Suhail Chaudhry, Katerina Goudevenou, Antonia Rotolo, David F Tough, Nicholas N Smithers, Anna K Bassil, Trevor D Chapman, Nicola R Harker, Olena Barbash, Peter Tummino, Niam Al-Mahdi, Andrea C Haynes, Leanne Cutler, BaoChau Le, Amin Rahemtulla, Irene Roberts, Maurits Kleijnen, Jason Witherington, Nigel J Parr, Rab K Prinjha, Anastasios Karadimitris
Publikováno v:
Blood. 122:878-878
Despite the therapeutic advances that followed the introduction of new immunomodulatory drugs and proteasome inhibitors, multiple myeloma (MM) remains an incurable malignancy and eventually all patients develop and succumb to chemo-refractory disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c97ef105b7f244c6aa64ac95f63fcb0
https://doi.org/10.1182/blood.v122.21.878.878
https://doi.org/10.1182/blood.v122.21.878.878